Developing antibodies to target specific protein splice variants
Official title: DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE Abs
Funded at Abbratech, INC. · NIH-11013261 · Data updated 2026-11-12
This study is working on a new way to find and test special antibodies that can help us understand and treat diseases like cancer by focusing on how proteins are made in different forms, which can change how they behave in the body.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abbratech, INC. NIH-funded |
| Lab location | 1 site (Branford, UNITED STATES) |
| Project start | September 20, 2024 |
| Project end | March 19, 2026 |
| Funding year | 2024 |
| Award (this year) | $205,926 |
| NIH project number | 1R44GM156476-01 |
| Project ID | NIH-11013261 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers or other diseases where alternative splicing plays a significant role.
✕Less likely to help
Patients with conditions unrelated to alternative splicing may not benefit from this research.
What this research studies
This research aims to create a platform for identifying and validating antibodies that specifically target splice-junction sites of protein isoforms. By utilizing innovative phage display technology, the project will validate existing antibodies and generate new ones to address the challenges posed by alternative splicing, which is crucial for understanding diseases like cancer. The research will involve techniques such as western blotting and flow cytometry to ensure the effectiveness of these antibodies. Ultimately, this work could lead to better diagnostic and therapeutic options for patients affected by conditions related to alternative splicing.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and targeted therapies for patients with diseases linked to alternative splicing.
How similar studies have gone: Other research has shown promise in targeting splice variants with antibodies, indicating potential success for this novel approach.
Where this research is happening
-
Abbratech, INC.
Branford, United States Active
Researchers
- Principal investigator: Weiner, Michael P — Abbratech, INC.
- Study coordinator: Weiner, Michael P
Related research
Other NIH-funded projects on the same topics.
-
Antibody Platform for Protein Isoform Splice-Junctions
A fast-track NIH grant aims to create antibodies that specifically recognize unique splice-junctions in proteins, helping to better understand and treat diseases linked to alternative splicing.
-
Creating special antibodies to find disease-related protein changes
This project aims to create new tools, called antibodies, that can find specific changes in proteins linked to various diseases, including cancer.
-
Developing antibodies to fight COVID-19 using advanced technology
This study is working on developing special antibodies that can fight the COVID-19 virus, using a new method to make sure they can keep up with any changes the virus might make, which could help improve treatments for COVID-19 and other infections.
-
Developing antibodies to target specific cancer mutations
This study is working on new antibodies that can help the immune system better recognize and attack cancer cells with a specific KRAS mutation, aiming to make treatments more effective and safer for patients with these types of cancers.
-
Validating antibodies for detecting modified proteins
This study is working to make sure that the tools scientists use to find certain proteins in the lab are more accurate and reliable, which will help improve research and treatments for patients.
-
A platform for quickly creating and testing antibodies
This study is working on a new way to quickly create and test special proteins called antibodies that can help treat diseases, so patients can get better treatments faster and more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.